ABT - Embedded Expectations Analysis - 2021 03 10
Abbott Laboratories (ABT:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 21.9x Uniform P/E. At these levels, the market has bullish expectations for the firm, and management is confident about meeting their 2021 EPS guidance, their COVID-19 testing capacity, and their new EPD and Nutrition product launchesSpecifically, management is confident they can meet their $5 EPS guidance in 2021, sustain COVID-19 testing in 2022, and maintain a strong balance sheet going forward. Moreover, they are confident their new lateral flow tests can identify infectious people and they have the capacity conduct over 50 million tests per month. They are also confident the pandemic has accelerated digital transformation and that their new cardiac rhythm defibrillation products are capable of offering remote monitoring and digitally connected care. Furthermore, they are confident new Established Pharmaceuticals Division (EPD) and Nutrition division product launches can drive the needed returns for those businesses, that they continue to build Alinity's test menu, and that the new Neuromodulation platform will change how patients get the results of their outcomes
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a range of health care products. The company's reportable segments are: established pharmaceutical products, which includes a range of generic pharmaceuticals; diagnostic products, which includes a range of diagnostic systems and tests; nutritional products, which includes a range of pediatric and adult nutritional products; and medical devices, which includes a range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.